Art

J-GLOBAL ID：201902258987844452   Reference number：19A1741179

Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study

ニボルマブ難治性粘膜黒色腫の日本人患者におけるイピリムマブの治療効果:症例シリーズ研究

Author (11)： Saijo Ken (Department of Medical Oncology, Tohoku University Hospital) ,  Imai Hiroo (Department of Medical Oncology, Tohoku University Hospital) ,  Ouchi Kota (Department of Medical Oncology, Tohoku University Hospital) ,  Okada Yoshinari (Department of Medical Oncology, Tohoku University Hospital) ,  Sato Yuko (Department of Medical Oncology, Tohoku University Hospital) ,  Komine Keigo (Department of Medical Oncology, Tohoku University Hospital) ,  Takahashi Masahiro (Department of Medical Oncology, Tohoku University Hospital) ,  Takahashi Shin (Department of Medical Oncology, Tohoku University Hospital) ,  Shirota Hidekazu (Department of Medical Oncology, Tohoku University Hospital) ,  Takahashi Masanobu (Department of Medical Oncology, Tohoku University Hospital) ,  Ishioka Chikashi (Department of Medical Oncology, Tohoku University Hospital)
Material： Tohoku Journal of Experimental Medicine  (Tohoku J Exp Med)
Volume： 248  Issue： 1  Page： 37-43(J-STAGE)  Publication year： 2019 
JST Material Number： G0649A  ISSN： 0040-8727  CODEN： TJEMAO  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *malignant melanoma ,...
Semi thesaurus term： *Ipilimumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1741179&from=J-GLOBAL&jstjournalNo=G0649A") }}

Author keywords (5)： anti-CTLA4 antibody ,  anti-PD-1 antibody ,  immune checkpoint inhibitor ,  immune-related adverse event ,  mucosal melanoma

JST classification (2)： Skin tumors(=neoplasms)  (GF04000X) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (18)：

• Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schob, O., Mannhart, M. & Oweira, H. (2017) Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Clin. Oncol. (R. Coll. Radiol.), 29, 218-230.
• Agrawal, S., Feng, Y., Roy, A., Kollia, G. & Lestini, B. (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J. Immunother. Cancer, 4, 72.
• Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Kong, B., Liniker, E., Guminski, A., Parente, P., Andrews, M.C., et al. (2016) Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br. J. Cancer, 114, 1084-1089.
• Chang, A.E., Karnell, L.H. & Menck, H.R. (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer, 83, 1664-1678.
• D’Angelo, S.P., Larkin, J., Sosman, J.A., Lebbe, C., Brady, B., Neyns, B., Schmidt, H., Hassel, J.C., Hodi, F.S., Lorigan, P., Savage, K.J., Miller, W.H. Jr., Mohr, P., Marquez-Rodas, I., Charles, J., et al. (2017) Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J. Clin. Oncol., 35, 226-235.

Terms in the title (9)： ニボルマブ ,  粘膜 ,  黒色腫 ,  日本人 ,  患者 ,  イピリムマブ ,  治療効果 ,  症例シリーズ ,  研究